Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab

@article{Saenger2014BloodME,
  title={Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab},
  author={Yvonne M. Saenger and Jay Magidson and Bobby Chi-Hung Liaw and Ellen H de Moll and Sara Harcharik and Yichun Fu and Karl Wassmann and David Fisher and John M. Kirkwood and William K. Oh and Philip Friedlander},
  journal={Clinical Cancer Research},
  year={2014},
  volume={20},
  pages={3310 - 3318}
}
Purpose: Tremelimumab (ticilimumab, Pfizer), is a monoclonal antibody (mAb) targeting cytotoxic T lymphocyte–associated antigen-4 (CTLA-4). Ipilimumab (Yervoy, BMS), another anti-CTLA-4 antibody, is approved by the U.S. Federal Drug Administration (FDA). Biomarkers are needed to identify the subset of patients who will achieve tumor control with CTLA-4 blockade. Experimental Design: Pretreatment peripheral blood samples from 218 patients with melanoma who were refractory to prior therapy and… Expand
Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab
TLDR
This is the largest blood-based biomarker study of a checkpoint inhibitor, tremelimumab, which demonstrates a validated pre-treatment mRNA classifier model that predicts clinical response and identifies non-responding patients at baseline prior to treatment. Expand
A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
TLDR
It is hypothesize that immune system modulation induced by immune checkpoint blockade results in peripheral blood gene expression changes that are detectable prior to clinical onset of severe diarrhea, and identifies a whole-blood mRNA signature predictive of a clinically relevant irAE in patients treated with immune checkpoints blockade. Expand
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
TLDR
For intra-tumoral biomarkers, expression of the PD-1 ligand PD-L1 has been found to be of some predictive value for anti-PD-1-directed therapy for NSCLC and melanoma. Expand
Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma
TLDR
In this review, prognostic and predictive biomarkers that are an active area of research are outlined and certain transcriptomic signatures are already used in the clinic, albeit not routinely, to prognosticate patients. Expand
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
TLDR
PD-L1 is the best studied biomarker for PD-1 ICI response, and all published biomarkers for ICI therapy are outlined and potential candidate markers for future research are highlighted. Expand
Identification of PLA2G7 as a novel biomarker of diffuse large B cell lymphoma
  • Weili Zheng, Qiaochu Lin, Mohammed Awal Issah, Ziyuan Liao, Jianzhen Shen
  • Medicine
  • BMC cancer
  • 2021
TLDR
PLA2G7 may represent an important diagnostic, prognostic, or therapeutic biomarker in patients with DLBCL and is found to be closely linked to tumor microenvironmental composition. Expand
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
TLDR
The insights gained from these biomarker studies can guide rational combinatorial strategies such as CDK4/6 inhibitor/fractionated radiotherapy/HDACi in conjunction with ICBs to maximize therapeutic benefits. Expand
Systematic evaluation of immune regulation and modulation
TLDR
Recommendations will focus on the unique collection and assay requirements for the analysis of various samples as well as the high-throughput assays to evaluate potential biomarkers. Expand
A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes
TLDR
Dic(1;7) in MDS establishes a specific transcriptional program driven by a unique epigenomic signature that underlie the hypo-expression of more than 50% of 1q-deregulated genes, despite trisomy. Expand
A panel of three oxidative stress-related genes predicts overall survival in ovarian cancer patients received platinum-based chemotherapy
TLDR
Evidence was provided that a panel of three oxidative stress-related gene signature had prognostic values for ovarian cancer patients received platinum-based chemotherapy, and it was suggested that patients with elder age, higher pathological grades and advanced tumor stages in low-risk score group could benefit from platinum- based chemotherapy. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 57 REFERENCES
Clinical development of the anti-CTLA-4 antibody tremelimumab.
  • A. Ribas
  • Medicine
  • Seminars in oncology
  • 2010
TLDR
The lack of survival advantage in the early analysis of a phase III clinical trial comparing tremelimumab with standard chemotherapy for metastatic melanoma highlights the importance of gaining a better understanding of how this antibody modulates the human immune system and how to better select patients for this mode of therapy. Expand
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
TLDR
Tremelimumab is a fully human monoclonal antibody specific for human cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, CD152) in clinical development for patients with cancer and its IgG(2) isotype minimizes the possibility of cytot toxic effects on activated T lymphocytes and cytokine release syndrome. Expand
An immune-active tumor microenvironment favors clinical response to ipilimumab
TLDR
These results support the proposed mechanism of action of ipilimumab, suggesting that cell-mediated immune responses play an important role in the antitumor activity of ipILimumab. Expand
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
TLDR
Tremelimumab showed an objective response rate of 6.6%, with all responses being durable ≥170 days since enrollment, suggesting a potential role for tremelimumAB in melanoma. Expand
Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types
TLDR
Estimating response rates using standard Response Evaluation Criteria in Solid Tumors (RECIST) or modified World Health Organization criteria or progression-free survival does not accurately capture the potential for clinical benefit for ipilimumab-treated patients. Expand
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
  • A. Ribas, R. Kefford, +21 authors A. Hauschild
  • Medicine, Mathematics
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
TLDR
This study failed to demonstrate a statistically significant survival advantage of treatment with tremelimumab over standard-of-care chemotherapy in first-line treatment of patients with metastatic melanoma. Expand
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
TLDR
Administration of CTLA4-blocking antibody tremelimumab to patients with advanced melanoma results in a subset of patients with long-lived tumor responses, and clustering according to T-cell activation or memory markers separated patients with clinical response and most patients with inflammatory toxicity into a common subgroup. Expand
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
TLDR
Baseline expression of immune-related tumor biomarkers and a post-treatment increase in TILs may be positively associated with ipilimumab clinical activity, and further studies are required to determine the predictive value of these and other potential biomarkers associated with clinical response to ipil balances. Expand
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion
TLDR
This study did not identify any safety concerns when tremelimumab was administered as a 1-hour infusion and the overall side effect profile was consistent with prior experiences with anti-CTLA4 antibodies. Expand
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
TLDR
In patients with advanced melanoma, including those who had had disease progression while they had been receiving ipilimumab, treatment with lambrolizumab resulted in a high rate of sustained tumor regression, with mainly grade 1 or 2 toxic effects. Expand
...
1
2
3
4
5
...